BioCentury
ARTICLE | Company News

Ambrx, Zhejiang Medicine deal

June 24, 2013 7:00 AM UTC

Ambrx granted Zhejiang rights in China to develop and commercialize Ambrx's ARX788 to treat breast cancer. The antibody-drug conjugate (ADC) targets epidermal growth factor receptor 2 ( EGFR2; HER2...